Research News
View articles by month and year
-
Tykerb and Xeloda Seem to Shrink HER2-Positive Breast Cancer That’s Spread to Brain
A very small, very early study suggests the combination of Tykerb and Xeloda shrinks HER2-positive breast cancer lesions in the brain without radiation.
-
T-DM1 Works Better on Advanced-Stage, HER2-Positive Cancer Than Standard Meds
A study found that women diagnosed with advanced-stage, HER2-positive breast cancer that had stopped responding to a standard regimen lived longer without the cancer growing when they got the experimental medicine T-DM1 compared to women who got a different regimen.
-
Xeloda Doesn’t Seem to Reduce Recurrence Risk
A new study shows that the risk of recurrence is the same whether or not Xeloda was added to a standard adjuvant chemotherapy regimen for early-stage breast cancer with a high risk of recurrence.
-
Halaven Approved by FDA to Treat Metastatic Breast Cancer
The FDA has approved a new chemotherapy medicine, Halaven (chemical name: eribulin), to treat metastatic breast cancer that already has been treated with other chemotherapy medicines.
-
Experimental Eribulin May Help Treat Various Types of Metastatic Breast Cancer
Research suggests that the experimental medicine eribulin may be a good treatment for various types of metastatic breast cancer that have stopped responding or failed to respond to other treatments.
-
Xeloda Reduces Recurrence Risk After Surgery but Causes More Serious Side Effects
The chemotherapy medicine Xeloda (chemical name: capecitabine) shows some promise in reducing the risk of early-stage breast cancer coming back, but the risk of side effects may outweigh the benefits.
-
Older Women Do Better on Conventional Chemo Compared to Xeloda
Research shows that women older than 65 do better on standard intravenous chemotherapy after surgery to remove early-stage breast cancer than Xeloda (chemical name: capecitabine), an oral chemotherapy.
-
Xeloda and Avastin Combo Better Than Xeloda Alone for Metastatic Disease
The combination of Xeloda (chemical name: capecitabine) and Avastin (chemical name: bevacizumab) has been shown to stop metastatic breast cancer from growing longer than Xeloda alone.
-
Cancers Resistant to Anthracyclines May Respond to Taxotere-Xeloda Combo
A new study suggests that breast cancer that is resistant to an anthracycline may respond to a combination of two other chemotherapies, Taxotere (chemical name: docetaxel) and Xeloda (chemical name: capecitabine).
-
Xeloda Less Effective Than Standard Chemo for Older Women
Xeloda (chemcial name capecitabine) isn't as good as traditional IV chemotherapy at reducing the risk of breast cancer coming back in women older than 65 diagnosed with early-stage or locally advanced breast cancer (cancer that hadn't metastasized).
